Danish drugmaker Novo Nordisk said several hundred counterfeit units of its diabetes drug Ozempic were being distributed in ...

The implications for Eli Lilly and Novo Nordisk seem pretty clear: The immediate removal of a rival for the massive revenues ...

Denmark’s economy was reshaped by Novo Nordisk and obesity drugs. That identity is now under attack on multiple fronts, from ...

An ex-manager for Novo Nordisk Inc. reached a settlement in her lawsuit alleging the healthcare company failed to accommodate her disabilities, retaliated against her, and wrongfully terminated her.

Novo Nordisk focused on a unique argument in federal appeals court on Tuesday in a case that will consider the extent to ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

This positive financial performance coincides with Lexicon’s announcement of a major licensing agreement with Novo Nordisk for the development and commercialization of its obesity drug candidate, ...

In this week’s edition of InnovationRx, we look at Trump's massive health agency layoffs, Palantir’s trade secret lawsuit, ...

Shares of Lexicon Pharmaceuticals LXRX have jumped 30% after signing a licensing deal for its pre-clinical obesity drug LX9851 with pharma giant Novo Nordisk NVO last week. Per the deal terms ...

Shares of Lexicon Pharmaceuticals LXRX have jumped 30% after signing a licensing deal for its pre-clinical obesity drug LX9851 with pharma giant Novo Nordisk NVO last week. Per the deal terms, Lexicon ...